Panchkula, India – Pharmaffiliates Private Limited, a global leader in reference standards and research support services, proudly announces the successful development and commercialization of several high-value impurity standards, further solidifying its position as a trusted partner to the pharmaceutical industry.

The newly developed products include:

PA 16 71520 – Prochlorperazine Maleate - Impurity C (EP/BP)
PA 18 0381056 – (R)-N-(3-(1,3-Dioxoisoindolin-2-yl)-2-hydroxypropyl)-N-(4-(3-oxomorpholino)phenyl)nitrous Amide
PA 19 07670 / PA 19 0061042 – (1RS,4SR)-4-(4-Chlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine
PA 19 18530 – Spironolactone Epimer Mixture
PA 19 21530 – 1,3,4,6-Tetra-O-sulfo-ß-D-fructofuranosyl a-D-Glucopyranoside 2,3,4-Tris(hydrogen sulfate) Heptapota
PA 20 01600 – Tacrolimus Hydroxy Acid Impurity
PA 20 3801000 – N-(2-(3,4-Dihydroxyphenyl)-2-hydroxyethyl)-N-(2-(1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-)
These innovative developments mark a significant step forward in Pharmaffiliates’ ongoing mission to provide reliable, high-purity impurity standards that support regulatory compliance, quality assurance, and pharmaceutical R&D across global markets.

Speaking on the achievement, Dr. A.K. Sabhawal, Managing Director of Pharmaffiliates, said:
“Each successful development reflects our scientific expertise, commitment to innovation, and customer-centric approach. These impurity standards will greatly contribute to the pharmaceutical industry by enabling more robust quality control and drug safety validations.”

With decades of excellence in custom synthesis, impurity profiling, reference standards, and CRDMO services, Pharmaffiliates continues to expand its global footprint, reinforcing its reputation as a trusted partner in advancing pharmaceutical science.